Core Viewpoint - The company, Shuoshi Biotechnology (688399), has announced a forecast for a significant increase in losses for the year 2025, with expected net losses ranging from 29.4 million to 44 million yuan, compared to a loss of 200.17 thousand yuan in the previous year [4]. Financial Performance - The forecasted net profit attributable to the parent company for 2025 is expected to be a loss of 29.4 million to 44 million yuan, while the non-recurring net profit is projected to be a loss of 81.9 million to 123 million yuan, compared to a loss of 71.8 million yuan in the previous year [4]. - The company's price-to-book ratio (LF) is approximately 2.03 times, and the price-to-sales ratio (TTM) is about 17.79 times based on the latest closing price [4]. Business Operations - The company specializes in in vitro diagnostic reagents and related testing instruments [15]. - Despite stable development in its main business, the company has faced challenges due to intensified industry competition and ongoing medical procurement policies, leading to a decrease in revenue from self-produced testing reagents [15]. - The company has implemented cost reduction and efficiency enhancement measures, aiming to maintain a stable gross profit margin compared to the previous year [15]. - The company has focused on improving the collection of accounts receivable, resulting in a gradual decrease in long-aged accounts receivable balances [15]. - The company has reduced government subsidies received during the reporting period [15]. Research and Development - The company continues to prioritize research and development investments, maintaining a relatively high intensity of R&D spending despite a year-on-year decline [15]. - The company is focusing on refining its core product lines and enhancing its overall solution capabilities in product development [15].